Compare TSBK & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSBK | CHRS |
|---|---|---|
| Founded | 1915 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.8M | 291.5M |
| IPO Year | 1997 | 2014 |
| Metric | TSBK | CHRS |
|---|---|---|
| Price | $37.42 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 16.3K | ★ 1.8M |
| Earning Date | 04-28-2026 | 06-01-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | 21.93 | ★ 472.00 |
| EPS | 1.04 | ★ 1.43 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $88.67 |
| Revenue Next Year | N/A | $28.64 |
| P/E Ratio | $36.80 | ★ $1.18 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.51 | $0.72 |
| 52 Week High | $40.41 | $2.62 |
| Indicator | TSBK | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 41.81 |
| Support Level | $37.74 | $1.55 |
| Resistance Level | $38.18 | $1.75 |
| Average True Range (ATR) | 0.87 | 0.11 |
| MACD | -0.14 | -0.00 |
| Stochastic Oscillator | 25.31 | 12.79 |
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.